Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status

Cancer Research

Volumn 62, Issue 3, 2002, Pages 781-788

  Szepeshazi, Karoly ^a   Schally, Andrew V ^a   Halmos, Gabor ^a   Armatis, Patricia ^a   Hebert, Francine ^a   Sun, Baodong ^a   Feil, Anita ^a   Kiaris, Hippokratis ^a   Nagy, Attila ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLINODOXORUBICIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; OCTAPEPTIDE; PROTEIN P53; SOMATOSTATIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; IMMUNOBLOTTING; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOXORUBICIN; GENES, P53; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MUTATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PYRROLES; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036468833     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer
2. New directions in the treatment of colorectal cancer: A look to the future
3. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
4. Clinical implications of p53 mutations
5. WAF1/CIP1 via C/EBP
6. Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin
7. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
8. Targeted cytotoxic somatostatin analogs: A modern approach to the therapy of various cancers
9. Administration of L-GnRH-PE-66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice
10. Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa
11. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer
12. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae
13. DOTA-lanreotide: A novel somatostatin analog for tumor diagnosis and therapy
14. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology
15. The binding of bombesin and somatostatin and their analogs to human colon cancers
16. Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose in tumor patients
17. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxombicin
18. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2- pyrrolinodoxorubicin
19. Receptor autoradio-graphic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastrointestinal adenocarcinoma samples: Where are they really located?
20. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238
21. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238
22. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers
23. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
24. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells
25. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer
26. Human ovarian cancers express somatostatin receptors
27. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in pancreatic cancer
28. 3]octreotide: The Rotterdam experience with more than 1000 patients
29. Somatostatin receptor subtypes sst1, sst2, sst3, and sst5 expression in human pituitary, gastmentero-pancreatic and mammary tumors: Comparison of mRNA analysis with receptor autoradiography
30. Immunohistochemical localization of somatostatin receptors sst2A in human tumors
31. Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma
32. No loss of sst receptors gene expression in advanced stages of colorectal cancer
33. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection
34. Tumour markers of prognosis in colorectal cancer
35. TabBO: A model reflecting common molecular features of androgen-independent prostate cancer
36. Infrequent expression of p21 is related to altered p53 protein in pancreatic carcinoma
37. Effect of mutation and conformation on the function of p53 in colorectal cancer
38. The puzzle of PCNA's many partners
39. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
40. WAF1/CIP1 response to genotoxic agents in wild-type TP53 expressing breast primary tumors